Literature DB >> 26490005

Diminished Progression of Periapical Lesions with Zoledronic Acid in Ovariectomized Rats.

Marcelo Tadahiro Wayama1, Hitoshi Yoshimura2, Seigo Ohba3, Hisato Yoshida2, Shinpei Matsuda2, Junichi Kobayashi2, Motohiro Kobayashi4, João Eduardo Gomes Filho5, Kazuo Sano6.   

Abstract

INTRODUCTION: The aim of this study was to investigate the effects of systemically administered zoledronic acid (ZOL) on the progression of periapical lesions in estrogen-deficient rats.
METHODS: Female Wistar rats were divided into the following groups: SHAM-veh, sham surgery treated with vehicle (physiological saline); OVX-veh, ovariectomy treated with vehicle; SHAM-ZOL, sham surgery treated with ZOL; and OVX-ZOL, ovariectomy treated with ZOL. Vehicle or ZOL was administered intravenously once a week for 4 weeks. The pulp of the mandibular first molar of all rats was exposed to the oral environment to induce a periapical lesion, and the lesions were analyzed after 7 and 30 days. The mandibles were examined by micro-computed tomographic imaging and histopathologic, histometric, and immunohistochemical analyses.
RESULTS: Histopathologically, the OVX-veh group had more severe inflammation and bone loss and a larger number of cells that were positive for tartrate-resistant acid phosphatase compared with the SHAM-veh and OVX-ZOL groups; the SHAM-veh and OVX-ZOL groups were similar to each other. The SHAM-ZOL group had the lowest magnitude of these conditions. Tomographically, the OVX-veh group had greater bone loss than the other groups at both time points. The SHAM-veh, SHAM-ZOL, and OVX-ZOL groups had similar bone loss at both time points. In the sagittal section on day 30, the SHAM-ZOL group had lower bone loss compared with the SHAM-veh and OVX-ZOL groups.
CONCLUSIONS: The hypoestrogenic condition aggravates the progression of periapical lesions. ZOL therapy may help contain bone destruction of periapical lesions.
Copyright © 2015 American Association of Endodontists. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bisphosphonate; estrogen deficiency; osteonecrosis

Mesh:

Substances:

Year:  2015        PMID: 26490005     DOI: 10.1016/j.joen.2015.08.029

Source DB:  PubMed          Journal:  J Endod        ISSN: 0099-2399            Impact factor:   4.171


  4 in total

1.  Preexisting Periapical Inflammatory Condition Exacerbates Tooth Extraction-induced Bisphosphonate-related Osteonecrosis of the Jaw Lesions in Mice.

Authors:  Minju Song; Abdullah Alshaikh; Terresa Kim; Sol Kim; Michelle Dang; Shebli Mehrazarin; Ki-Hyuk Shin; Mo Kang; No-Hee Park; Reuben H Kim
Journal:  J Endod       Date:  2016-09-13       Impact factor: 4.171

2.  The effect of melatonin on prevention of bisphosphonate-related osteonecrosis of the jaw: an animal study in rats.

Authors:  Afshin Yadegari; Atousa Aminzadeh; Sam Seyyedkhamesi; Maedeh Aminian
Journal:  J Korean Assoc Oral Maxillofac Surg       Date:  2020-08-31

3.  Zoledronate treatment duration is linked to bisphosphonate-related osteonecrosis of the jaw prevalence in rice rats with generalized periodontitis.

Authors:  Jonathan G Messer; Jessica M Jiron; Jorge L Mendieta Calle; Evelyn J Castillo; Ronnie Israel; Ean G Phillips; Joshua F Yarrow; Catherine Van Poznak; Lakshmyya Kesavalu; Donald B Kimmel; J Ignacio Aguirre
Journal:  Oral Dis       Date:  2019-02-19       Impact factor: 3.511

4.  Periapical status in patients affected by osteoporosis: A retrospective clinical study.

Authors:  Erika Cadoni; Francesca Ideo; Giuseppe Marongiu; Silvia Mezzena; Luca Frigau; Quirico Mela; Antonio Capone; Henry F Duncan; Elisabetta Cotti
Journal:  Clin Exp Dent Res       Date:  2022-06-14
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.